(NASDAQ: NKTX) Nkarta's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.51%.
Nkarta's earnings in 2026 is -$117,324,000.On average, 8 Wall Street analysts forecast NKTX's earnings for 2026 to be -$129,691,009, with the lowest NKTX earnings forecast at -$136,874,976, and the highest NKTX earnings forecast at -$120,780,885. On average, 8 Wall Street analysts forecast NKTX's earnings for 2027 to be -$124,956,610, with the lowest NKTX earnings forecast at -$158,634,587, and the highest NKTX earnings forecast at -$109,048,744.
In 2028, NKTX is forecast to generate -$114,026,667 in earnings, with the lowest earnings forecast at -$123,538,440 and the highest earnings forecast at -$105,288,443.